Cost-effectiveness of nivolumab vs. ipilimumab/nivolumab vs. trifluridine/tipiracil or mFOLFOX6/cetuximab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer.

被引：0
|
作者：
Chu, Jacqueline N.
Choi, Jin G.
Ostvar, Sassan
Torchia, James Anthony
Reynolds, Kerry Lynn
Gainor, Justin F.
Chung, Daniel C.
Clark, Jeffrey W.
Hur, Chin
机构：
[1] Massachusetts Gen Hosp, Boston, MA USA
[2] Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA USA
[3] Dana Farber Canc Inst, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e15134
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15134
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Phase II study of durvalumab monotherapy in patients with previously treated microsatellite instability-high/mismatch repair-deficient or POLE-mutated metastatic or unresectable colorectal cancer
    Oh, Chung Ryul
    Kim, Jeong Eun
    Hong, Yong Sang
    Kim, Sun Young
    Ahn, Joong Bae
    Baek, Ji Yeon
    Lee, Myung-Ah
    Kang, Myoung Joo
    Cho, Sang Hee
    Beom, Seung-Hoon
    Kim, Tae Won
    INTERNATIONAL JOURNAL OF CANCER, 2022, 150 (12) : 2038 - 2045
  • [42] Cost-Effectiveness of First-Line Versus Second-Line Pembrolizumab or Chemotherapy in Patients With Microsatellite-Instability-High/Mismatch Repair-Deficient Advanced Colorectal Cancer
    Tan, Chongqing
    Li, Sini
    Zeng, Xiaohui
    Peng, Liubao
    Ye, Peng
    Qin, Shuxia
    Wang, Liting
    Wu, Meiyu
    Wan, Xiaomin
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [43] Nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Two-year clinical update.
    Lenz, Heinz-Josef
    Lonardi, Sara
    Zagonel, Vittorina
    Van Cutsem, Eric
    Limon, M. Luisa
    Wong, Mark
    Hendlisz, Alain
    Aglietta, Massimo
    Garcia-Alfonso, Pilar
    Neyns, Bart
    Gelsomino, Fabio
    Cardin, Dana Backlund
    Dragovich, Tomislav
    Shah, Usman
    Yang, Jing
    Ledeine, Jean-Marie
    Overman, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [44] Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164
    Le, Dung T.
    Kim, Tae Won
    Van Cutsem, Eric
    Geva, Ravit
    Jager, Dirk
    Hara, Hiroki
    Burge, Matthew
    O'Neil, Bert
    Kavan, Petr
    Yoshino, Takayuki
    Guimbaud, Rosine
    Taniguchi, Hiroya
    Elez, Elena
    Al-Batran, Salah-Eddin
    Boland, Patrick M.
    Crocenzi, Todd
    Atreya, Chloe E.
    Cui, Yi
    Dai, Tong
    Marinello, Patricia
    Diaz, Luis A., Jr.
    Andre, Thierry
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (01) : 11 - +
  • [45] Exploratory Analysis of Janus Kinase 1 (JAK1) Loss-of-Function (LoF) Mutations in Patients with DNA Mismatch Repair-Deficient/Microsatellite Instability-High (dMMR/MSI-H) Metastatic Colorectal Cancer (mCRC) Treated with Nivolumab plus Ipilimumab in CheckMate-142
    Kopetz, S.
    Andre, T.
    Overman, M. J.
    Zagonel, V.
    Lonardi, S.
    Aglietta, M.
    Gelsomino, F.
    McDermott, R.
    Wong, K. Y. M.
    Hendlisz, A.
    Alfonso, P. G.
    Lenz, H. J.
    Walsh, A.
    Moss, R. A.
    Greenawalt, D.
    Cao, Z. A.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2018, 20 (03): : S3 - S3
  • [46] Exploratory analysis of Janus kinase 1 (JAK1) loss-of-function (LoF) mutations in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC) treated with nivolumab plus ipilimumab in CheckMate-142
    Kopetz, Scott
    Andre, Theirry
    Overman, Michael J.
    Zagonel, Vittorina
    Lonardi, Sara
    Aglietta, Massimo
    Gelsomino, Fabio
    McDermott, Ray
    Wong, Ka Yeung Mark
    Hendlisz, Alain
    Garcia Alfonso, Pilar
    Lenz, Heinz-Josef
    Walsh, Alice
    Moss, Rebecca A.
    Greenawalt, Danielle
    Cao, Z. Alexander
    CANCER RESEARCH, 2018, 78 (13)
  • [47] Combination of nivolumab (nivo) 1 ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 Study
    Lonardi, S.
    Andre, T.
    Wong, K. Y. M.
    Morse, M.
    McDermott, R.
    Hill, A.
    Hendlisz, A.
    Lenz, H.
    Leach, J.
    Moss, R. A.
    Cao, Z. A.
    Ledeine, J.
    Kopetz, S.
    Overman, M.
    ANNALS OF ONCOLOGY, 2017, 28 : 3 - 3
  • [48] Cost-effectiveness of pembrolizumab compared with chemotherapy in the US for women with previously treated deficient mismatch repair or high microsatellite instability unresectable or metastatic endometrial cancer
    Thurgar, Elizabeth
    Gouldson, Mark
    Matthijsse, Suzette
    Amonkar, Mayur
    Marinello, Patricia
    Upadhyay, Navneet
    Nwankwo, Chizoba
    Aguiar-Ibanez, Raquel
    JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) : 675 - 688
  • [49] Systematic literature review and network meta-analysis of pembrolizumab versus other interventions for previously untreated, unresectable or metastatic, microsatellite instability-high or mismatch repair-deficient colorectal cancer
    Jin, He
    Amonkar, Mayur
    Aguiar-Ibanez, Raquel
    Thosar, Manasi
    Chase, Monica
    Keeping, Sam
    FUTURE ONCOLOGY, 2022, 18 (17) : 2155 - 2171
  • [50] Combination of nivolumab (nivo) plus ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 study.
    Andre, Thierry
    Lonardi, Sara
    Wong, Ka Yeung Mark
    Morse, Michael
    McDermott, Raymond S.
    Hill, Andrew Graham
    Hendlisz, Alain
    Lenz, Heinz-Josef
    Leach, Joseph W.
    Moss, Rebecca Anne
    Cao, Z. Alexander
    Ledeine, Jean-Marie
    Chan, Emily
    Kopetz, Scott
    Michael, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345